|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
11153821 |
| 006 |
m o d |
| 007 |
cr cn||||||||| |
| 008 |
070802s2007 enka ob 001 0 eng d |
| 005 |
20240510213159.7 |
| 010 |
|
|
|a 2006049868
|
| 019 |
|
|
|a 730500505
|a 1055395150
|a 1062921691
|a 1081276599
|
| 020 |
|
|
|a 9780123693938
|
| 020 |
|
|
|a 0123693934
|
| 020 |
|
|
|a 9780080465975
|q (electronic bk.)
|
| 020 |
|
|
|a 0080465978
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)162130366
|z (OCoLC)730500505
|z (OCoLC)1055395150
|z (OCoLC)1062921691
|z (OCoLC)1081276599
|
| 035 |
|
9 |
|a (OCLCCM-CC)162130366
|
| 037 |
|
|
|a 113098:113186
|b Elsevier Science & Technology
|n http://www.sciencedirect.com
|
| 040 |
|
|
|a OPELS
|b eng
|e pn
|c OPELS
|d OCLCG
|d OCLCQ
|d N$T
|d OCLCQ
|d OCLCF
|d OCLCQ
|d CHVBK
|d NLGGC
|d YDXCP
|d OCLCQ
|d TOA
|d AGLDB
|d OCLCO
|d JBG
|d VNS
|d OCLCO
|d D6H
|d OCLCO
|d OCLCQ
|d VTS
|d REC
|d VT2
|d OCLCO
|d OCLCQ
|d WYU
|d OCLCA
|d S9I
|d STF
|d OCLCO
|d LEAUB
|d OCLCO
|d M8D
|d OCLCO
|d OCLCA
|
| 049 |
|
|
|a MAIN
|
| 050 |
|
4 |
|a RM301.63
|b .T36 2007eb
|
| 060 |
|
4 |
|a 2006 N-124
|
| 060 |
|
4 |
|a QV 744
|b T185 2007
|
| 072 |
|
7 |
|a MED
|x 023000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 072000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 058170
|2 bisacsh
|
| 245 |
0 |
0 |
|a Target validation in drug discovery /
|c editors, Brian W. Metcalf and Susan Dillon.
|
| 260 |
|
|
|a Amsterdam ;
|a Boston :
|b Academic Press,
|c ©2007.
|
| 300 |
|
|
|a 1 online resource (xii, 279 pages) :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a data file
|2 rda
|
| 520 |
|
|
|a This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.
|
| 505 |
0 |
|
|a Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Drug development.
|0 http://id.loc.gov/authorities/subjects/sh97007921
|
| 650 |
|
0 |
|a Drugs
|x Testing.
|0 http://id.loc.gov/authorities/subjects/sh85039755
|
| 650 |
|
0 |
|a High throughput screening (Drug development)
|0 http://id.loc.gov/authorities/subjects/sh2001002949
|
| 650 |
|
6 |
|a Médicaments
|x Développement.
|
| 650 |
|
6 |
|a Médicaments
|x Essais cliniques.
|
| 650 |
|
6 |
|a Criblage à haut débit (Développement des médicaments)
|
| 650 |
|
7 |
|a MEDICAL
|x Drug Guides.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacy.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Nursing
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Drugs
|x Testing.
|2 fast
|0 (OCoLC)fst00898940
|
| 650 |
|
7 |
|a High throughput screening (Drug development)
|2 fast
|0 (OCoLC)fst00956496
|
| 650 |
|
7 |
|a Médicaments
|x Mise au point.
|2 ram
|
| 650 |
|
7 |
|a Médicaments
|x Essais cliniques.
|2 ram
|
| 650 |
|
7 |
|a Criblage pharmacologique.
|2 ram
|
| 650 |
1 |
2 |
|a Drug Design.
|
| 650 |
2 |
2 |
|a Drug Delivery Systems.
|
| 650 |
2 |
2 |
|a Technology, Pharmaceutical.
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Metcalf, Brian W.
|
| 700 |
1 |
|
|a Dillon, Susan,
|d 1952-
|0 http://id.loc.gov/authorities/names/n2006058857
|
| 776 |
0 |
8 |
|i Print version:
|t Target validation in drug discovery.
|d Amsterdam ; Boston : Academic Press, ©2007
|z 0123693934
|z 9780123693938
|w (DLC) 2006049868
|w (OCoLC)70823305
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a oclccm
|
| 999 |
f |
f |
|i 7fcdc821-9ea9-50bd-97fc-8bc51be2837c
|s b530a574-237e-5cef-b801-96b0086a444c
|
| 928 |
|
|
|t Library of Congress classification
|a RM301.63 .T36 2007eb
|l Online
|c UC-FullText
|u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=182182
|z eBooks on EBSCOhost
|g ebooks
|i 12241191
|
